Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma
Open Access
- 2 November 2023
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 7 (1) , 1-13
Abstract
Molecular subtyping of lung squamous cell carcinoma (LUSC) has been performed at the genomic, transcriptomic, and proteomic level. However, LUSC stratification based on tissue metabolomics is still lacking. Combining high-mass-resolution imaging mass spectrometry with consensus clustering, four tumor- and four stroma-specific subtypes with distinct metabolite patterns were identified in 330 LUSC patients. The first tumor subtype T1 negatively correlated with DNA damage and immunological features including CD3, CD8, and PD-L1. The same features positively correlated with the tumor subtype T2. Tumor subtype T4 was associated with high PD-L1 expression. Compared with the status of subtypes T1 and T4, patients with subtype T3 had improved prognosis, and T3 was an independent prognostic factor with regard to UICC stage. Similarly, stroma subtypes were linked to distinct immunological features and metabolic pathways. Stroma subtype S4 had a better prognosis than S2. Subsequently, analyses based on an independent LUSC cohort treated by neoadjuvant therapy revealed that the S2 stroma subtype was associated with chemotherapy resistance. Clinically relevant patient subtypes as determined by tissue-based spatial metabolomics are a valuable addition to existing molecular classification systems. Metabolic differences among the subtypes and their associations with immunological features may contribute to the improvement of personalized therapy.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (01ZX1610B and 01KT1615)
- Deutsche Forschungsgemeinschaft (SFB 824 C4, CRC/Transregio 205/1)
- China Scholarship Council (No. 201906210076)
This publication has 49 references indexed in Scilit:
- A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancerAnnals of Oncology, 2013
- Analysis of Tissue Specimens by Matrix-Assisted Laser Desorption/Ionization Imaging Mass Spectrometry in Biological and Clinical ResearchChemical Reviews, 2013
- Comprehensive genomic characterization of squamous cell lung cancersNature, 2012
- Links between metabolism and cancerGenes & Development, 2012
- A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissueNature Protocols, 2012
- The DNA damage response and cancer therapyNature, 2012
- Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell TypesClinical Cancer Research, 2010
- Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancerCellular & Molecular Immunology, 2010
- Strategies for discovering novel cancer biomarkers through utilization of emerging technologiesNature Clinical Practice Oncology, 2008
- B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 ExpressionClinical Cancer Research, 2004